February 26, 2025, Basel, Switzerland – TenNor Therapeutics presented its novel multi-targeting drug conjugation technology as a solution to antimicrobial resistance (AMR) problems at the 9th AMR Conference.

The AMR Conference is a one-stop shop to catch up with the latest trends in the development of AMR products, by covering scientific, regulatory, financial and policy topics. It is a platform for start-ups, small medium entities, big pharma, academia, investors and public institutions to discuss strategies and specific challenges faced by the innovation ecosystem in bringing new antimicrobial treatments and diagnostics to the market.

Link to the AMR Conference:

https://amr-conference.com/

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late stage of clinical development, targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com